All articles tagged with #dlbcl
This study used spatial transcriptomics, proteomics, and genomics to analyze the tumor immune microenvironments in diffuse large B-cell lymphoma (DLBCL), identifying distinct cellular neighborhoods and communication patterns that influence immune cell function and tumor behavior, with implications for targeted immunotherapy.
Merck & Co. has reported promising phase 2 trial results for its ROR1-directed antibody-drug conjugate (ADC), zilovertamab vedotin, showing a 100% complete response rate in patients with diffuse large B-cell lymphoma (DLBCL) at certain doses. Despite some safety concerns at higher doses, the company plans to advance the low dose into a phase 3 trial, comparing it to the standard R-CHOP regimen. The trial will focus on progression-free survival as the primary endpoint, with complete response and overall survival as secondary endpoints.
Mary Bird Perkins Cancer Center has expanded its services to include phase 1 clinical trials, starting with a trial to treat large B cell lymphoma. Phase 1 trials are the earliest stage of testing for new therapies and require a higher level of expertise and resources. The center has previously offered phase 2 and 3 trials and began expanding its program after hiring Dr. Victor Lin as its medical director for clinical research.